Enanta Pharmaceuticals, Inc. today announced results from the PEARL-II, PEARL-III, PEARL-IV and TURQUOISE-II studies. These studies are the remaining four phase 3 studies of the six phase 3 registrational studies being conducted by AbbVie for the treatment of genotype 1 hepatitis C virus infection using a regimen containing Enanta’s lead protease inhibitor ABT-450.
Drugmaker AbbVie said it expects a hepatitis C treatment to go on sale in the U.S. this year after completing testing for the liver disease drug. AbbVie said its latest trial results show the therapy was ...
In Uganda the prescription of three antiretroviral drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge in Uganda, and a new study in The Journal of Clinical Pharmacology explores the impact food insecurity may have on treating pregnant women.
In Uganda the prescription of three antiretroviral (ARV) drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge in Uganda, and a new study in The Journal of Clinical Pharmacology explores the impact food insecurity may have on treating pregnant women.
Enanta Announces Results From Four All-Oral, Interferon-Free, Phase 3 Studies
AstraZeneca today announced that on February 1, 2014, it completed its acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance.
MOUNTAIN VIEW, Calif. -- VIVUS, Inc. , a biopharmaceutical company commercializing Qsymia(R) (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today provided a business ...
Research and Markets has announced the addition of the "Concise Analysis of Drug Solubility Technology: Spray Dr
Bristol-Myers Squibb Company and Pfizer Inc. today announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the efficacy and safety of Eliquis compared to warfarin for reducing the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation .
Would You Like to Record Your Side Effects for later use? It is Free and Easy. >> Start Today
Spread the word: Share, Email, Print
How Effective was Ritonavir for You? Share Your Positive and Negative Experiences.blog comments powered by Disqus